Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids

Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids

Salman H Siddiqui,1,2 Ian D Pavord,3,4 Neil C Barnes,5,6 Alessandro Guasconi,7 Sally Lettis,8 Steven Pascoe,9 Stefano Petruzzelli7 1University of Leicester, Leicester, UK; 2National Institute for Health Research Leicester Biomedical Research Centre, Leicester, UK; 3Respiratory Theme, National Insti...

Full description

Bibliographic Details
Main Authors:	Siddiqui SH, Pavord ID, Barnes NC, Guasconi A, Lettis S, Pascoe S, Petruzzelli S
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-11-01
Series:	International Journal of COPD
Subjects:	lung function FEV1 chronic obstructive pulmonary disease ICS
Online Access:	https://www.dovepress.com/blood-eosinophils-a-biomarker-of-copd-exacerbation-reduction-with-inha-peer-reviewed-article-COPD

Similar Items

COPD patients prescribed inhaled corticosteroid in primary care: time for re-assessment based on exacerbation rate and blood eosinophils?
by: Osman Savran, et al.
Published: (2021-02-01)

Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist
by: Yang HH, et al.
Published: (2017-08-01)

Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE2SPOND rationale and study design
by: Rennard SI, et al.
Published: (2016-08-01)

A Cross-Sectional Study Assessing Appropriateness Of Inhaled Corticosteroid Treatment In Primary And Secondary Care Patients With COPD In Sweden
by: Sulku J, et al.
Published: (2019-11-01)

The dose of inhaled corticosteroids in patients with COPD: when less is better
by: Izquierdo JL, et al.
Published: (2018-10-01)

Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials
by: Dave Singh, et al.
Published: (2020-09-01)

Assessment of high-dose inhalational corticosteroids vs systemic corticosteroids in acute exacerbations of COPD in diabetic patients
by: A. S. Magdy, et al.
Published: (2020-01-01)

Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population
by: Vestbo J, et al.
Published: (2019-04-01)

Use of capnography for prediction of obstruction severity in non-intubated COPD and asthma patients
by: Barak Pertzov, et al.
Published: (2021-05-01)

Blood eosinophil count in patients with COPD on inhaled corticosteroids in comparison with healthy smoker and nonsmoker controls
by: Noha Othman Ahmed, et al.
Published: (2021-01-01)

Methacholine challenge test as indicator for add on inhaled corticosteroids in COPD patients
by: M. Hantera, et al.
Published: (2014-04-01)

Blood Eosinophil Counts in Chronic Obstructive Pulmonary Disease: A Biomarker of Inhaled Corticosteroid Effects
by: Dave Singh
Published: (2020-07-01)

Study of changes in Flow Volume curves in obese middle-aged individuals with obstructive pulmonary disease
by: C. Anithu, et al.
Published: (2013-10-01)

Characterization Associated with the Frequent Severe Exacerbator Phenotype in COPD Patients
by: Wu YK, et al.
Published: (2021-08-01)

Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD
by: Bhattacharya A, et al.
Published: (2016-06-01)

Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis
by: Timothy H. Harries, et al.
Published: (2020-01-01)

Sputum cell counts to manage prednisone-dependent asthma: effects on FEV1 and eosinophilic exacerbations
by: Afia Aziz-Ur-Rehman, et al.
Published: (2017-04-01)

Different outcomes of pulmonary rehabilitation in patients with COPD with or without exacerbations
by: G.G. Riario-Sforza, et al.
Published: (2005-09-01)

Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD
by: Ke X, et al.
Published: (2016-07-01)

Validity of the Handheld Expiratory Flowmeter for COPD Screening in the Primary Care Setting of China
by: Chen S, et al.
Published: (2021-07-01)

Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trials
by: Jieun Kang, et al.
Published: (2021-02-01)

Benefit/Risk Profile of Single-Inhaler Triple Therapy in COPD
by: Bourbeau J, et al.
Published: (2021-03-01)

The sputum transcriptome better predicts COPD exacerbations after the withdrawal of inhaled corticosteroids than sputum eosinophils
by: Benedikt Ditz, et al.
Published: (2021-07-01)

Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts
by: Se Hee Lee, et al.
Published: (2019-03-01)

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US
by: Rajagopalan K, et al.
Published: (2018-11-01)

Spirometric changes during exacerbations of COPD: a post hoc analysis of the WISDOM trial
by: Henrik Watz, et al.
Published: (2018-12-01)

Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
by: Pascoe S, et al.
Published: (2016-08-01)

Inhaled corticosteroids can reduce osteoporosis in female patients with COPD
by: Liu SF, et al.
Published: (2016-07-01)

Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial
by: Jinping Zheng, et al.
Published: (2021-03-01)

Evaluation of Superiority of FEV1/VC Over FEV1/FVC for Classification of Pulmonary Disorders
by: Majid Mirsadraee, et al.
Published: (2015-11-01)

Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations
by: Calverley PM, et al.
Published: (2016-02-01)

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
by: Mario Cazzola, et al.
Published: (2019-11-01)

Daily home-based spirometry during withdrawal of inhaled corticosteroid in severe to very severe chronic obstructive pulmonary disease
by: Rodriguez-Roisin R, et al.
Published: (2016-08-01)

Association Between Adherence to Maintenance Medication in Patients with COPD and Acute Exacerbation Occurrence and Cost in China: A Retrospective Cohort Database Study
by: Chen R, et al.
Published: (2020-05-01)

Quality of life and adherence to inhaled corticosteroids and tiotropium in COPD are related
by: Koehorst-ter Huurne K, et al.
Published: (2016-07-01)

Gender Disparity in Lung Function Abnormalities among a Population Exposed to Particulate Matter Concentration in Ambient Air in the National Capital Region, India
by: Chandrasekharan Nair Kesavachandran, et al.
Published: (2015-01-01)

FVC, FEV1 and FEV1% in Male Tobacco Industry Workers
by: Chandra Rani Sarkar, et al.
Published: (2011-12-01)

Shall We Focus on the Eosinophil to Guide Treatment with Systemic Corticosteroids during Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)? CON
by: Pedro J Marcos, et al.
Published: (2018-06-01)

Exacerbations of COPD
by: Pavord ID, et al.
Published: (2016-02-01)

Prognostic marker for severe acute exacerbation of chronic obstructive pulmonary disease: analysis of diffusing capacity of the lung for carbon monoxide (DLCO) and forced expiratory volume in one second (FEV1)
by: Juwhan Choi, et al.
Published: (2021-05-01)